Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
Provided By GlobeNewswire
Last update: Jun 30, 2025
As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025
Read more at globenewswire.com
